Liver Cancer

July 1st 2023

Patients with unresectable hepatocellular carcinoma, a type of liver cancer, obtained a survival benefit over four years of follow-up with a treatment regimen of Imfinzi and Imjudo.

June 28th 2023

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

June 3rd 2023

Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.

May 25th 2023

Patients born outside of the U.S. may have improved liver cancer survival rates compared with U.S.-born patients, although more research is needed to determine what may be driving this effect, research showed.